ArticleMethods in molecular biology (Clifton, N.J.)2026
Assays for Plasma ADAMTS13 Activity and Inhibitors Using Recombinant FRETS-VWF73 Peptide.
Article in Methods in molecular biology (Clifton, N.J.), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Analytical validation and harmonization of activity-based protease assays: requirements for clinical translation.Analytical and bioanalytical chemistry · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Thrombotic thrombocytopenic purpura (TTP) is a life-threatening thrombotic microangiopathy caused by severe deficiency of plasma ADAMTS13 activity. ADAMTS13 cleaves ultra-large von Willebrand factor (ULVWF) multimers, thus preventing the pathological accumulation of platelet-VWF aggregates at sites of vascular injury. The deficiency of ADAMTS13 can be congenital or more commonly immune-mediated, involving the formation of autoantibodies that bind and inactivate plasma ADAMTS13 activity. A simple, rapid, and cost-effective assay is crucial for the diagnosis of TTP and for the conduction of translational research relevant to ADAMTS13 function. Here, we describe a FRETS-rVWF73 assay for ADAMTS13 activity and inhibition, starting from the peptide substrate expression, purification, labeling, detailed assay protocol, and potential pitfalls. This assay can be used to quantify ADAMTS13 enzymatic activity and inhibition in various biological conditions for translational research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.